As the voice of the research-based pharmaceutical industry in the UK, we work to improve the UK as a competitive place for the pharmaceutical industry. We do this by engaging with Government and regulators on policy issues of interest to the pharmaceutical industry.
Through partnerships and a coherent policy framework across issues relating to research, development, manufacturing, regulation, market conditions and patient access, we believe that the industry will be able to bring leading-edge treatments and technologies to patients, whilst maintaining the UK’s global leadership in life sciences.
We, therefore, meet regularly with parliamentarians from all parties to inform them about the industry and its contribution to the health and wealth of the country, as well as to provide expert input to policy discussions.
We work with ministers, officials and parliamentarians across Government and the Houses of Parliament to seek ways to improve patient access to treatment and healthcare outcomes and to support a vibrant pharmaceutical industry in the UK.
We provide a joint-secretarial support to the All Party Parliamentary Group for Life Sciences, which provides a platform for parliamentarians from all parties to explore issues and policies of common interest.
Our policy and parliamentary work includes providing briefings on policy issues, giving evidence to select committees and responding to Government consultations.
The ABPI is at the heart of a health sector-wide effort to establish consensus on key Brexit issues including medicines regulation, UK and EU trading relationships, access to talent, and the future of UK science.
In August 2017, the Life Sciences Industrial Strategy was published – a report to Government from the Life Sciences sector, including the ABPI.
A marketing authorisation works to ensure that when a medicine reaches a patient it works in the same high quality way every time.
MMIP represents the voice of medicines manufacturers in the UK. It was established jointly by the Government and the biopharmaceutical industry in 2014 to ensure that the UK is recognised by the global medicines industry as a world-class advanced centre for medicines manufacturing.
Delegated Regulation to the Falsified Medicines Directive (FMD) 2011/62/EU, published on the 9 February 2016, will come in to force by February 2019. The new regulation will require manufacturers to place safety features on all medicines and contribute financially to the establishment of an IT verification system that will allow the assessment of the authenticity of a medicine at the time of supply to the patient.